As expected, the MYC oncogene is a central driver in multiple cancers, such as breast cancer,6 liver tumor,7 colorectal carcinoma,8 and prostatic neoplasia.9 High and/or aberrant Myc expression occurs in >70% human cancers and is related to poor prognosis and aggressive conditions.10–12 Thus, the high recurrence of Myc overexpression in cancers and its universal role in transcriptional regulation deems it as a tricky oncoprotein for targeting. The gene discussed is MYC; the disease is cancer.